| Q48278153 | (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. |
| Q91062309 | 3-year freedom from progression following 68GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial |
| Q90619517 | 68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery |
| Q38167489 | A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. |
| Q38957244 | A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy |
| Q39900411 | A novel method of bladder neck imbrication to improve early urinary continence following robotic-assisted radical prostatectomy. |
| Q79130704 | A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer |
| Q50660769 | A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. |
| Q57423302 | Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression Are Early Events in Prostate Cancer Development and Are Associated with Poor Prognosis |
| Q83875358 | Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens |
| Q38261253 | Adverse effects of androgen-deprivation therapy in prostate cancer and their management |
| Q48309899 | Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. |
| Q57027477 | An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy |
| Q96117600 | Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer |
| Q36946259 | Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. |
| Q37125439 | AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments. |
| Q86735108 | Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy |
| Q37618298 | Computational imaging reveals shape differences between normal and malignant prostates on MRI. |
| Q47575119 | Decision-Making in Prostate Cancer – Choosing Active Surveillance Over Other Treatment Options: A Literature Review |
| Q50184973 | Decision-Making in Prostate Cancer: Active Surveillance Over Other Treatment Options |
| Q91740840 | Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of |
| Q53682862 | Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. |
| Q88896407 | Editorial Comment |
| Q48288989 | Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. |
| Q52591137 | Enduring epigenetic landmarks define the cancer microenvironment. |
| Q38765391 | Enhancing active surveillance of prostate cancer: the potential of exercise medicine |
| Q54687568 | Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death |
| Q45750299 | Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important? |
| Q38611750 | Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer |
| Q96128908 | Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE) |
| Q38630336 | Focal irreversible electroporation as primary treatment for localized prostate cancer. |
| Q40440753 | Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control |
| Q90737311 | Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostat |
| Q54414821 | Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. |
| Q43607238 | Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development |
| Q55333927 | Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. |
| Q83050070 | HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer |
| Q37944906 | High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. |
| Q85567760 | High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse |
| Q58782540 | Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings |
| Q50109408 | Imaging: MRI improves cost and accuracy of prostate cancer biopsy |
| Q46392395 | Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. |
| Q58784302 | Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments |
| Q38063556 | Informed prostate cancer risk-adjusted testing: a new paradigm. |
| Q34490212 | Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer |
| Q48370281 | Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. |
| Q63966381 | International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy |
| Q91280616 | Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment |
| Q75233086 | Is year of radical prostatectomy a predictor of outcome in prostate cancer? |
| Q45769213 | Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. |
| Q51606266 | Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer. |
| Q83698264 | Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer |
| Q91081272 | MRI improves active surveillance of prostate cancer however biopsy is still crucial |
| Q44435099 | Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer |
| Q40170568 | Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. |
| Q37538185 | Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer |
| Q92136350 | Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort |
| Q40102454 | Outcomes of transperineal template-guided prostate biopsy in 409 patients. |
| Q112643167 | Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase |
| Q88209404 | Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy |
| Q40541815 | Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies |
| Q38858888 | Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up |
| Q47658667 | Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation |
| Q43901559 | Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients |
| Q56969116 | Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy |
| Q48227663 | Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. |
| Q57282806 | Prostate Cancer in 432 men under the age of 50 years in the Prostate Specific Antigen era - a new outlook |
| Q92763182 | Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic |
| Q37444820 | Quality of life three years after diagnosis of localised prostate cancer: population based cohort study |
| Q39042948 | Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study |
| Q50422339 | Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings. |
| Q57484099 | Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50 |
| Q48085721 | Reply to Patrick H. Tuliao and Koon Ho Rha's letter to the editor re: James E. Thompson, Sam Egger, Maret Böhm, et al. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning cur |
| Q39390030 | Robot-assisted laparoscopic prostatectomy: analysis of an experienced open surgeon's learning curve after 300 procedures. |
| Q51729743 | Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years. |
| Q43527973 | Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. |
| Q53137796 | Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide. |
| Q47256842 | Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases. |
| Q42630766 | Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases |
| Q35883123 | Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer |
| Q40327460 | The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer. |
| Q91874457 | The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies |
| Q90388643 | The distribution of prostate cancer recurrences on 68 Ga-PSMA PET/CT after radical prostatectomy with pathological node positive extended lymph node dissection |
| Q38711300 | The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. |
| Q26849794 | The role of magnetic resonance imaging in the diagnosis and management of prostate cancer |
| Q48023733 | Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. |
| Q38568583 | Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment |
| Q91079282 | Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literat |
| Q77639615 | Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer |
| Q91457462 | Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer |
| Q57423301 | Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy |